Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Adjunctive Therapy in MDD (BLESS)
NCT03697603Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change from Baseline in Montgomery-Asberg Depression Rating Scale Total Score at 6 weeks. Started Jul 2018; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03697603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697603.